Our mission is to discover, develop and deliver innovative therapies that improve the lives of those affected by cancer.
Led by a team with a deep understanding of the biology of cancer and extensive drug discovery, development and commercialization experience, we are rapidly advancing two novel therapies for people living with cancer.
Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. In 2020, G1 out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.